Raptor spirals down on FDA delay on nephropathic cystinosis drug
This article was originally published in Scrip
Executive Summary
Shares of Raptor Pharmaceutical tumbled 12.3% in after-hours trading on 21 December on word the US FDA delayed its decision by three months on RP103 as a treatment for a rare genetic lysosomal storage disorder known as nephropathic cystinosis, the company revealed shortly after the US markets closed.